236 related articles for article (PubMed ID: 36072938)
1. What do we do now that the long-acting growth hormone is here?
Miller BS
Front Endocrinol (Lausanne); 2022; 13():980979. PubMed ID: 36072938
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients.
Miller BS; Yuen KCJ
Drug Des Devel Ther; 2022; 16():2055-2066. PubMed ID: 35791404
[TBL] [Abstract][Full Text] [Related]
3. Somatrogon injection for the treatment of pediatric growth hormone deficiency with comparison to other LAGH products.
Velazquez EP; Miller BS; Yuen KCJ
Expert Rev Endocrinol Metab; 2024; 19(1):1-10. PubMed ID: 38112103
[TBL] [Abstract][Full Text] [Related]
4. Developments in the Management of Growth Hormone Deficiency: Clinical Utility of Somapacitan.
Miller BS; Blair J; Horikawa R; Linglart A; Yuen KCJ
Drug Des Devel Ther; 2024; 18():291-306. PubMed ID: 38333899
[TBL] [Abstract][Full Text] [Related]
5. Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis.
Zhu J; Yuan K; Rana S; Jakki SL; Bhat AS; Liang L; Wang C
Sci Rep; 2024 Apr; 14(1):8061. PubMed ID: 38580693
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis.
Mameli C; Orso M; Calcaterra V; Wasniewska MG; Aversa T; Granato S; Bruschini P; Guadagni L; d'Angela D; Spandonaro F; Polistena B; Zuccotti G
Pharmacol Res; 2023 Jul; 193():106805. PubMed ID: 37236413
[TBL] [Abstract][Full Text] [Related]
7. Guidance for the treatment of adult growth hormone deficiency with somapacitan, a long-acting growth hormone preparation.
Bidlingmaier M; Biller BMK; Clemmons D; Jørgensen JOL; Nishioka H; Takahashi Y
Front Endocrinol (Lausanne); 2022; 13():1040046. PubMed ID: 36619571
[TBL] [Abstract][Full Text] [Related]
8. Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial.
Mori J; Ohata Y; Fujisawa Y; Sato Y; Röhrich S; Rasmussen MH; Bang RB; Horikawa R
Clin Endocrinol (Oxf); 2024 Apr; 100(4):389-398. PubMed ID: 38368603
[TBL] [Abstract][Full Text] [Related]
9. Effective GH Replacement With Once-weekly Somapacitan vs Daily GH in Children with GHD: 3-year Results From REAL 3.
Sävendahl L; Battelino T; Højby Rasmussen M; Brod M; Saenger P; Horikawa R
J Clin Endocrinol Metab; 2022 Apr; 107(5):1357-1367. PubMed ID: 34964458
[TBL] [Abstract][Full Text] [Related]
10. Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency.
Garner T; Clayton P; Højby M; Murray P; Stevens A
J Clin Endocrinol Metab; 2024 Apr; 109(5):1214-1221. PubMed ID: 38066644
[TBL] [Abstract][Full Text] [Related]
11. Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial.
Sävendahl L; Battelino T; Brod M; Højby Rasmussen M; Horikawa R; Juul RV; Saenger P;
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1847-61. PubMed ID: 31917835
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in pre-pubertal children with pediatric growth hormone deficiency: 12-month results from a phase 3 clinical trial of once-weekly somatrogon versus once-daily somatropin.
Loftus J; Quitmann J; Valluri SR
Curr Med Res Opin; 2024 Feb; 40(2):175-184. PubMed ID: 38053515
[TBL] [Abstract][Full Text] [Related]
13. Usefulness and Potential Pitfalls of Long-Acting Growth Hormone Analogs.
Yuen KCJ; Miller BS; Boguszewski CL; Hoffman AR
Front Endocrinol (Lausanne); 2021; 12():637209. PubMed ID: 33716988
[TBL] [Abstract][Full Text] [Related]
14. Long-Acting Growth Hormone Preparations - Current Status and Future Considerations.
Miller BS; Velazquez E; Yuen KCJ
J Clin Endocrinol Metab; 2020 Jun; 105(6):e2121-33. PubMed ID: 31676901
[TBL] [Abstract][Full Text] [Related]
15. Somapacitan: a long-acting growth hormone derivative for treatment of growth hormone deficiency.
Paton DM
Drugs Today (Barc); 2022 Oct; 58(10):509-517. PubMed ID: 36305544
[TBL] [Abstract][Full Text] [Related]
16. Comparing treatment with daily and long-acting growth hormone formulations in adults with growth hormone deficiency: Challenging issues, benefits, and risks.
Höybye C
Best Pract Res Clin Endocrinol Metab; 2023 Dec; 37(6):101788. PubMed ID: 37308376
[TBL] [Abstract][Full Text] [Related]
17. Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3.
Sävendahl L; Battelino T; Højby Rasmussen M; Brod M; Röhrich S; Saenger P; Horikawa R
J Clin Endocrinol Metab; 2023 Sep; 108(10):2569-2578. PubMed ID: 36995872
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness and cost-utility analysis of somatrogon once-weekly injections vs. daily growth hormone injection for treating paediatric growth hormone deficiency in Ireland.
Rivolo S; Loftus J; Peter B; Fahey M; Kongnakorn T
J Med Econ; 2023; 26(1):963-972. PubMed ID: 37527156
[TBL] [Abstract][Full Text] [Related]
19. Effective GH Replacement With Somapacitan in Children With GHD: REAL4 2-year Results and After Switch From Daily GH.
Miller BS; Blair JC; Rasmussen MH; Maniatis A; Mori J; Böttcher V; Kim HS; Bang RB; Polak M; Horikawa R
J Clin Endocrinol Metab; 2023 Nov; 108(12):3090-3099. PubMed ID: 37406251
[TBL] [Abstract][Full Text] [Related]
20. Weekly somapacitan had no adverse effects on glucose metabolism in adults with growth hormone deficiency.
Takahashi Y; Biller BMK; Fukuoka H; Ho KKY; Rasmussen MH; Nedjatian N; Sværke C; Yuen KCJ; Johannsson G
Pituitary; 2023 Feb; 26(1):57-72. PubMed ID: 36380045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
